Compare Bristol-Myers Squibb Co (BMY) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Hut 8 Corp — how do they compare? Bristol-Myers Squibb Co trades at $58.83 (market cap $116.30B), while Hut 8 Corp trades at $98.48 (market cap $11.07B). The key difference: Bristol-Myers Squibb Co is far larger — about 10.5× Hut 8 Corp's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| BMY | HUT | |
|---|---|---|
Market Cap | $116.30B | $11.07B |
Sector | Health | Technology |
52-Week High | $62.37 | $133.02 |
52-Week Low | $42.60 | $19.45 |
Enterprise Value | $152.24B | $11.33B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
HUT trades at $99.17, down 2.98% today, with a bearish technical signal. The company shows strong revenue growth potential but deep losses, with a net income margin of -109.77% in 2025. Recent news highlights its pivot to AI infrastructure, securing $16.8 billion in contracted revenue and closing a $4.25 billion investment-grade bond for data center projects.
Outlook is mixed: analyst consensus is strongly bullish with a $138.89 price target, but high valuation ratios and persistent negative cash flow from operations pose risks. The stock's near-term direction hinges on Q2 2026 earnings results and execution of its infrastructure expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
